iCAD
Inc. (Nasdaq: ICAD) announced that Noridian changed the reimbursement code
for electronic brachytherapy for non-melanoma skin cancers sending the stock price plunging $3.32 to close at $4.63.
Medicare reimbursement changes sink iCad
May 07, 2015 at 16:57 PM EDT
